Investigations from External Quality Assurance Programs Reveal a High Degree of Variation in the Laboratory Identification of Coagulation Factor Inhibitors

ABSTRACT

The laboratory has a key role in the initial detection of factor inhibitors and an ongoing role in the measurement of inhibitor titers during the course of inhibitor eradication therapy. The most commonly seen factor inhibitors are those directed against factor VIII (FVIII), usually detected either with the original or the Nijmegen-modified Bethesda assay. In addition, several circumstances can arise in which the laboratory may test samples that potentially reflect false identification of factor inhibitors. These include lupus anticoagulants and other events generally related to preanalytical variables, including incorrect sample presentations. This article reviews each of these elements, largely from the perspective of cross-laboratory studies undertaken within the framework of external quality assurance (EQA), a peer-laboratory process that aims to assess the ongoing performance of groups of similar laboratories. This review details the experience of the Royal College of Pathologists of Australasia Haematology Quality Assurance Program, and it also reflects on the experience of other EQA organizations. Our analysis reveals a wide variety of test practice among inhibitor testing laboratories, a wide variation in detected inhibitor levels in cross-tested samples, and substantial evidence of false-positive and false-negative detection of factor inhibitors. These findings hold some significance for the clinical management of patients affected by these inhibitors. There is still much need for standardization and improvement in factor inhibitor detection, and we hope that this report provides a basis for future improvements in this area.

KEYWORDS

Factor inhibitors - laboratory testing - proficiency testing - Bethesda - Nijmegen

REFERENCES

• 1 Verbruggen B. Diagnosis and quantification of factor VIII inhibitors.  Haemophilia. 2009;  , February 18 (Epub ahead of print)
• 2 Chitlur M, Warrier I, Rajpurkar M, Lusher J M. Inhibitors in factor IX deficiency: a report of the ISTH-SSC international FIX inhibitor registry (1997–2006).  Haemophilia. 2009;  15(5) 1027-1031
• 3 Favaloro E J, Posen J, Ramakrishna R et al.. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.  Blood Coagul Fibrinolysis. 2004;  15(8) 637-647
• 4 Ang A L, Kuperan P, Ng C H, Ng H J. Acquired factor V inhibitor. A problem-based systematic review.  Thromb Haemost. 2009;  101(5) 852-859
• 5 Favaloro E J, Wong R CW. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.  Semin Thromb Hemost. 2008;  34(4) 389-410
• 6 Pengo V, Tripodi A, Reber G et al.. Update of the guidelines for lupus anticoagulant detection.  J Thromb Haemost. 2009;  7(10) 1737-1740
• 7 Wong R CW, Favaloro E J. Clinical features, diagnosis, and management of the antiphospholipid syndrome.  Semin Thromb Hemost. 2008;  34(3) 295-304
• 8 Favaloro E J, Lippi G, Adcock D M. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?.  Semin Thromb Hemost. 2008;  34(7) 612-634
• 9 Favaloro E J, Bonar R, Duncan E et al.. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation.  Thromb Haemost. 2006;  96(1) 73-78
• 10 Favaloro E J, Bonar R, Duncan E et al.. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation.  Pathology. 2007;  39(5) 504-511
• 11 Verbruggen B, van Heerde W, Laros-van Gorkom B. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.  Semin Thromb Hemost. 2009;  35(8) 752-759
• 12 Sahud M A, Pratt K P, Zhukov O, Qu K, Thompson A R. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.  Haemophilia. 2007;  13(3) 317-322
• 13 Ling M, Duncan E M, Rodgers S E, Street A M, Lloyd J V. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.  J Thromb Haemost. 2003;  1(12) 2548-2553
• 14 Kasper C K, Aledort L M, Counts R B et al.. Letter: A more uniform measurement of factor VIII inhibitors.  Thromb Diath Haemorrh. 1975;  34(3) 869-872
• 15 Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.  Semin Thromb Hemost. 2009;  35(8) 760-768
• 16 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.  Thromb Haemost. 1995;  73(2) 247-251
• 17 Giles A R, Verbruggen B, Rivard G E, Teitel J, Walker I. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis . A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada.  Thromb Haemost. 1998;  79(4) 872-875
• 18 Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay.  Thromb Haemost. 2002;  88(2) 362-364
• 19 Reber G, Aurousseau M H, Dreyfus M et al.. Inter-laboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas.  Haemophilia. 1999;  5(4) 292-293
• 20 Lippi G, Favaloro E J. Activated partial thromboplastin time: new tricks for an old dogma.  Semin Thromb Hemost. 2008;  34(7) 604-611
• 21 Spreafico M, Peyvandi F. Combined factor V and factor VIII deficiency.  Semin Thromb Hemost. 2009;  35(4) 390-399
• 22 Lippi G, Salvagno G L, Adcock D M, Gelati M, Guidi G C, Favaloro E J. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample.  Int J Lab Hematol. 2009;  , February 7 (Epub ahead of print)
• 23 Kitchen S, Jennings I, Preston F E, Kitchen D P, Woods T AL, Walker I D. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK National External Assessment Service for blood coagulation.  Semin Thromb Hemost. 2009;  35 778-785
• 24 Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT Foundation.  Semin Thromb Hemost. 2009;  35 786-793
• 25 Peerschke E I, Castellone D D, Ledford-Kraemer M, Van Cott E M, Meijer P. NASCOLA Proficiency Testing Committee . Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.  Am J Clin Pathol. 2009;  131(4) 552-558
• 26 Favaloro E J, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K. (on behalf of RCPA Haematology QAP Haemostasis Committee) . Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.  Haemophilia. 2010;  , In press
• 27 Hay C R, Brown P, Collins P W, Keeling D M, Leisner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors' Organisation.  Br J Haematol. 2006;  133 591-605
• 28 Gringeri A, Mannucci P M. Italian Association of Haemophilia Centres . Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.  Haemophilia. 2005;  11(6) 611-619